405 related articles for article (PubMed ID: 30465228)
21. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
[TBL] [Abstract][Full Text] [Related]
22. Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Carroll C; Tappenden P; Rafia R; Hamilton J; Chambers D; Clowes M; Durrington P; Qureshi N; Wierzbicki AS
Pharmacoeconomics; 2017 May; 35(5):537-547. PubMed ID: 28285379
[TBL] [Abstract][Full Text] [Related]
23. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
[TBL] [Abstract][Full Text] [Related]
24. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
[TBL] [Abstract][Full Text] [Related]
25. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
[TBL] [Abstract][Full Text] [Related]
26. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Walton M; Sharif S; Simmonds M; Claxton L; Hodgson R
Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165
[TBL] [Abstract][Full Text] [Related]
27. Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Jones-Hughes T; Dunham J; Warren FC; Robinson S; Stephens P; Hoyle M
Pharmacoeconomics; 2018 Jan; 36(1):39-49. PubMed ID: 28914440
[TBL] [Abstract][Full Text] [Related]
28. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
[TBL] [Abstract][Full Text] [Related]
29. The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Cox E; Wade R; Peron M; Dietz KC; Eastwood A; Palmer S; Griffin S
Pharmacoeconomics; 2019 Sep; 37(9):1081-1091. PubMed ID: 30887470
[TBL] [Abstract][Full Text] [Related]
30. Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Whyte S; Gomersall T; Ren S; Wong R; Chambers D; Tappenden P
Pharmacoeconomics; 2017 Jul; 35(7):717-726. PubMed ID: 27943135
[TBL] [Abstract][Full Text] [Related]
31. Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Rafia R; Scope A; Harnan S; Stevens JW; Stevenson M; Lobo A
Pharmacoeconomics; 2016 Dec; 34(12):1241-1253. PubMed ID: 27480631
[TBL] [Abstract][Full Text] [Related]
32. Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pouwels XGLV; Petersohn S; Carrera VH; Denniston AK; Chalker A; Raatz H; Armstrong N; Shah D; Witlox W; Worthy G; Noake C; Riemsma R; Kleijnen J; Joore MA
Pharmacoeconomics; 2020 May; 38(5):431-441. PubMed ID: 31701471
[TBL] [Abstract][Full Text] [Related]
33. A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence.
Wade R; Hodgson R; Biswas M; Harden M; Woolacott N
Pharmacoeconomics; 2017 Feb; 35(2):203-213. PubMed ID: 27592020
[TBL] [Abstract][Full Text] [Related]
34. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
36. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
[TBL] [Abstract][Full Text] [Related]
37. Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bresnahan R; Houten R; Greenhalgh J; Nevitt S; Mahon J; Beale S; Boland A; Bhattacharyya D; Dundar Y; McEntee J; Gandhi S; Fleeman N; Chaplin M
Pharmacoecon Open; 2023 Jul; 7(4):525-536. PubMed ID: 37195551
[TBL] [Abstract][Full Text] [Related]
38. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.
Llewellyn A; Faria R; Woods B; Simmonds M; Lomas J; Woolacott N; Griffin S
Pharmacoeconomics; 2016 Oct; 34(10):981-92. PubMed ID: 27278217
[TBL] [Abstract][Full Text] [Related]
39. Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pandor A; Pollard D; Chico T; Henderson R; Stevenson M
Pharmacoeconomics; 2016 May; 34(5):463-77. PubMed ID: 26689783
[TBL] [Abstract][Full Text] [Related]
40. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]